Stockscreener 앱 받기
3.02
0.98%
-0.03
전일 마감가:
$3.05
열려 있는:
$3.05
하루 거래량:
390.87K
Relative Volume:
0.50
시가총액:
$238.96M
수익:
$130.42M
순이익/손실:
$18.64M
주가수익비율:
13.84
EPS:
0.2182
순현금흐름:
$4.05M
1주 성능:
-3.21%
1개월 성능:
-8.21%
6개월 성능:
-41.25%
1년 성능:
-68.90%
1일 변동 폭
$2.99
$3.06
1주일 범위
$2.98
$3.1091
52주 변동 폭
$2.87
$10.52
Niagen Bioscience Inc Stock (NAGE) Company Profile
명칭
Niagen Bioscience Inc
전화
310-388-6706
주소
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
3.02 | 242.13M | 130.42M | 18.64M | 4.05M | 0.2182 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-27 | 개시 | Canaccord Genuity | Buy |
| 2022-08-16 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-08-11 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | 개시 | ROTH Capital | Buy |
| 2019-10-16 | 개시 | Oppenheimer | Outperform |
| 2019-02-14 | 개시 | B. Riley FBR | Buy |
| 2017-11-27 | 재개 | H.C. Wainwright | Buy |
| 2017-09-25 | 개시 | Ladenburg Thalmann | Buy |
| 2017-01-03 | 개시 | Rodman & Renshaw | Buy |
모두보기
Niagen Bioscience Inc 주식(NAGE)의 최신 뉴스
Niagen Bioscience at canaccord growth conference: cash, science and growth By Investing.com - Investing.com India
Niagen Bioscience, Inc. (NASDAQ: NAGE) Share Price, NAGE Stock News, NAGE Share Price & Updates - Kalkine
HC Wainwright Forecasts Lower Earnings for Niagen Bioscience - MarketBeat
Niagen Bioscience, Inc. (NAGE) Stock Analysis: A 297% Upside Potential Awaits Investor Attention - DirectorsTalk Interviews
Niagen Bioscience launches Tru Niagen on Walmart.com - Investing.com India
HC Wainwright Predicts Weaker Earnings for Niagen Bioscience - MarketBeat
Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence - Yahoo Finance
NAGE Stock Price and Chart — NASDAQ:NAGE - TradingView
Sei Investments Co. Increases Holdings in Niagen Bioscience, Inc. $NAGE - MarketBeat
Niagen Bioscience, Inc. $NAGE Holdings Boosted by Renaissance Technologies LLC - MarketBeat
Niagen Bioscience (NAGE) On New Aging Study And The Case For A Higher Fair Value - Yahoo Finance
Niagen Bioscience (NAGE) Stock Sinks As Profit Cushion Thins - simplywall.st
Q2 2026 Niagen Bioscience Inc Earnings Call Transcript - GuruFocus
CCORF Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Niagen Bioscience Inc (NAGE) (Q2 2026) Earnings Call Highlights: - GuruFocus
Niagen Bioscience, Inc. Stock 12‑Month Price Target Cut to $12.08, Implies 248% Upside - TradingView
Earnings call transcript: Niagen Bioscience posts q2 2026 growth, lifts spending - Investing.com
Niagen Bioscience (NASDAQ:NAGE) Announces Quarterly Earnings Results, Meets Expectations - MarketBeat
Is Niagen Bioscience Inc (NAGE) Undervalued After Q2 Earnings Mi - GuruFocus
Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates - Yahoo Finance
Niagen Bioscience, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:NAGE) 2026-08-04 - Seeking Alpha
Niagen Bioscience Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Niagen Bioscience: Q2 Earnings Snapshot - barchart.com
Niagen Bioscience, Inc. (NAGE) Q2 FY2026 earnings call transcript - Yahoo Finance
Niagen Bioscience 2026: Revenue $29.79M, EPS $0.01— 10-Q Summary - TradingView
Press Release: Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results - 富途牛牛
[10-Q] Niagen Bioscience, Inc. Quarterly Earnings Report - Stock Titan
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results - Yahoo Finance
Niagen Bioscience (NAGE) Earnings Date and Reports 2026 - MarketBeat
Niagen Bioscience selects Evotec for rare disease drug studies - Investing.com
Niagen Bioscience selects Evotec for rare disease drug studies By Investing.com - Investing.com Nigeria
Arrowstreet Capital Limited Partnership Buys 761,685 Shares of Niagen Bioscience, Inc. $NAGE - MarketBeat
Niagen Bioscience, Inc. (OCD1) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Niagen Bioscience, Inc. (NAGE): Investor Outlook Highlights Potential 274% Upside - DirectorsTalk Interviews
Niagen Bioscience Inc expected to post earnings of 2 cents a shareEarnings Preview - TradingView
Niagen Bioscience, Inc. Revenue Breakdown – DUS:OCD1 - TradingView
Niagen Bioscience reports study on muscle aging markers By Investing.com - Investing.com Canada
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen - Business Wire
Niagen Bioscience reports study on muscle aging markers - Investing.com
Niagen Bioscience Inc (NAGE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference - Caledonian Record
NAGE|Niagen Bioscience Inc|Price:3.240|Chg%:+0.030 - TradingKey
Niagen Bioscience Inc (NAGE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Niagen Bioscience Inc (NAGE) Cash Flow - tradingkey.com
Niagen Bioscience Inc (NAGE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Niagen Bioscience Inc (NAGE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Niagen Bioscience, Inc. Revenue Breakdown – MUN:OCD1 - TradingView
Niagen Bioscience, Inc. Revenue Breakdown – TRADEGATE:OCD1 - TradingView
Niagen Bioscience Inc|Price:3.210|Chg%:+0.020 - TradingKey
Niagen Bioscience, Inc. (NAGE) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Niagen Bioscience Inc (NAGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):